Orthofix won't sell fixation lines, looks to strengthen ortho unit instead:
This article was originally published in Clinica
Orthofix International said it is holding on to its external and internal bone fixation products, less than two months after announcing it was looking for buyers for the business. Instead, the company said it will look to free up more cash by tightening operating costs and maximising the value of its orthopaedic business. Growth in Orthofix's orthopaedics business in 2007 was stymied by declining sales of external fixation devices, which fell 11%. Internal fixation sales, on the other hand, soared 48%, aided by the introduction of new products. Orthofix, headquartered in the Netherlands, had announced in February that it was looking to sell its orthopaedic fixation products to reduce debt and invest in its core spine business.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.